Get the Stockscreener App
8.2437
2.58%
-0.2763
Stoke Therapeutics Inc stock is traded at $8.2437, with a volume of 120.06K.
It is down -2.58% in the last 24 hours and down -21.92% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of nearly 50% of normal protein levels (haploinsufficiency).
See More
Previous Close:
$8.52
Open:
$8.44
24h Volume:
120.06K
Relative Volume:
0.17
Market Cap:
$443.86M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-3.4784
EPS:
-2.37
Net Cash Flow:
$-82.68M
1W Performance:
+1.84%
1M Performance:
-21.92%
6M Performance:
-42.64%
1Y Performance:
+21.17%
1-Day Range:
$8.24
$8.6094
1-Week Range:
$7.65
$8.6094
52-Week Range:
$5.60
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
8.245 | 443.86M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.03 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.80 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.20 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.18 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Rhumbline Advisers Acquires 2,787 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Los Angeles Capital Management LLC Has $479,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke, Biogen team to advance zorevunersen for Dravet patients - Dravet Syndrome News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Stoke Therapeutics Gains FDA Breakthrough for Epilepsy Drug - MSN
Stoke Therapeutics to Present at Upcoming Investor Conferences in March - Business Wire
Wedbush Research Analysts Cut Earnings Estimates for STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Buy” from Brokerages - Defense World
What is HC Wainwright's Estimate for STOK FY2025 Earnings? - MarketBeat
Stoke Therapeutics' (STOK) Buy Rating Reiterated at Chardan Capital - MarketBeat
Equities Analysts Offer Predictions for STOK Q1 Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings - Defense World
Trading (STOK) With Integrated Risk Controls - Stock Traders Daily
Stoke Therapeutics’ Collaboration with BioGen - Global Legal Chronicle
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital - Defense World
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MSN
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – Here’s Why - Defense World
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright - Defense World
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - BioSpace
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - Insights
Biogen and Stoke Therapeutics Enter into Collaboration to - GlobeNewswire
Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright - Smartphone Magazine
Biogen, Stoke partner for Dravet syndrome treatment By Investing.com - Investing.com Nigeria
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Benzinga
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
BTIG maintains Stoke Therapeutics stock with $29 target By Investing.com - Investing.com UK
HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating - Marketscreener.com
Biogen And Stoke Therapeutics Enter Into Collaboration -February 18, 2025 at 10:00 am EST - Marketscreener.com
Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating - TipRanks
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen -February 18, 2025 at 09:39 am EST - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com India
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha
Sector Update: Health Care Stocks Softer Wednesday Afternoon -February 12, 2025 at 01:47 pm EST - Marketscreener.com
SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Sector Update: Health Care Stocks Retreat Late Afternoon -February 12, 2025 at 03:54 pm EST - Marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat
Long Term Trading Analysis for (STOK) - Stock Traders Daily
Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Skorpios Trust | 10% Owner |
Dec 23 '24 |
Sale |
11.50 |
2,000,000 |
23,000,000 |
6,906,181 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):